Full Breakdown
Surge in NHS Mounjaro Prescriptions Amid Price Hikes
9/1/2025, 8:56:50 PM
Rapid Increase in Prescriptions
The National Health Service (NHS) in England is experiencing a significant surge in prescriptions for Mounjaro (tirzepatide), a medication initially approved for type 2 diabetes that has gained popularity as a weight-loss treatment. Recent data indicates that NHS prescriptions for Mounjaro have skyrocketed from 18,501 in May 2024 to over 147,000 in May 2025, averaging nearly 200 prescriptions per hour. This increase follows the drug's rollout to general practitioners (GPs) in June 2024, allowing broader access for patients with a body mass index (BMI) of 40 or higher and multiple obesity-related health issues.
Price Hikes and Accessibility Concerns
Despite the rising demand, the cost of Mounjaro is set to nearly triple, with private prescriptions increasing from £122 to £330 for the highest dose starting September 1, 2025. The 15mg dose will rise from £122 to £247.50, while the 5mg dose will increase from £92 to £135. This price hike has raised concerns among patients who have been self-funding their treatment, as many may find it increasingly unaffordable.
Julia Dore, a patient who has benefited from Mounjaro, expressed her frustration after losing weight and being told she no longer qualifies for NHS prescriptions due to her reduced BMI. She stated, "Now I’ve been told my only option for getting the injections on the NHS is to put the weight back on. That isn’t fair." This sentiment reflects a broader issue faced by many individuals who initially sought private treatment but later found themselves ineligible for NHS support.
Official Responses and Future Changes
In response to the rising costs and accessibility issues, the NHS has reached an agreement with Eli Lilly, the drug's manufacturer, to ensure continued supply and patient access at the new higher list prices. From April 2026, the eligibility criteria for NHS prescriptions will be relaxed, allowing individuals with a BMI of 35 or higher to qualify, along with those with four obesity-related conditions. However, experts warn that it could take up to 12 years for all eligible patients to receive treatment.
Criticism and Opposition
Critics argue that the current system is inequitable, as those who self-funded their treatment may be penalized for their proactive health choices. Professor Naveed Sattar from the University of Glasgow noted that many patients are considering regaining weight to qualify for NHS prescriptions, which could lead to serious health risks. He stated, "To fulfil the NHS criteria, some people are thinking their best choice is to come off the drugs and go back up to their previous weight."
Verbatim Quotes
- “‘Losing weight on Mounjaro has been absolutely life-changing.” — Julia Dore, Patient
- “‘The ongoing benefits are tremendous – while stopping would see them regain weight and suffer serious problems.” — Professor David Strain, University of Exeter Medical School
Conclusion
The surge in Mounjaro prescriptions highlights the growing recognition of obesity as a critical health issue in the UK. However, the rising costs and complex eligibility criteria for NHS prescriptions pose significant challenges for many patients. As the NHS prepares to adjust its guidelines, the future of weight-loss treatments remains uncertain for those navigating this evolving landscape.
